Novo Nordisk shares dive 9% after heart medicine fails trial

Share

📰 source: cnbc_topnews · 💼 business

novo nordisk shares dropped as much as 10% on friday after a late-stage trial for its heart drug ziltivekimab failed to reduce major adverse cardiovascular events compared to placebo. the study of over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease and elevated inflammation missed its primary endpoint. overall mortality was unchanged, though serious infections were more common with the drug.

chief scientific officer martin holst lange said the result doesn't change the company's strategic commitment to cardiovascular disease. analysts at jefferies and citi called the selloff disproportionate, but jefferies noted it removes one of novo's more credible non-obesity growth opportunities. shares were down 7.4% in copenhagen and 8.6% in premarket ads, turning negative for the year, coming into friday they were already down 7% year-to-date and about 70% off mid-2024 peak. the failure adds pressure as novo counts on pipeline including wegovy pill and cagrisema to compete with eli lilly, with q2 earnings due next week.


why it matters: failed heart drug removes a key non-obesity growth option, deepening novo's reliance on obesity meds and competitive pressure vs lilly.


source: cnbc_topnews
sentiment: -0.80 · impact: 0.70

Read more